- Home
- GERN vs ODTX Comparison
GERN vs ODTX Comparison
Compare GERN & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | ODTX |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | 258 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 808.3M | 794.2M |
| IPO Year | N/A | 2026 |
Fundamental Metrics
Financial Performance| Metric | GERN | ODTX |
|---|---|---|
| Price | $1.50 | $17.23 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.17 | N/A |
| AVG Volume (30 Days) | ★ 14.8M | 273.8K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $15.10 |
| 52 Week High | $2.01 | $20.00 |
Technical Indicators
Market Signals| Indicator | GERN | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 35.71 |
| Support Level | $1.44 | $15.10 |
| Resistance Level | $1.72 | $19.59 |
| Average True Range (ATR) | 0.09 | 1.41 |
| MACD | 0.03 | -0.18 |
| Stochastic Oscillator | 68.06 | 32.24 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.